Cenix BioScience Signs Research Service Agreement with Bayer Pharma AG
Complete the form below to unlock access to ALL audio articles.
Cenix BioScience GmbH (Cenix) has announced that is has signed a research service agreement with Bayer Pharma AG (Bayer).
Under the agreement, Cenix will undertake a target discovery project for an undisclosed disease indication by applying its longstanding industry-leading expertise in high throughput RNAi for genome-scale screening in advanced cell models.
Financial terms were not disclosed.